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ABSTRACT
Myelodysplastic syndromes (MDS) are a heterogeneous, clonal haematopoietic 
disorder, with ~1/3 of patients progressing to acute myeloid leukaemia (AML). Many 
elderly MDS patients do not tolerate intensive therapeutic regimens, and therefore 
have an unmet need for better tolerated therapies. 
Epigenetics is important in the pathogenesis of MDS/AML with DNA methylation, 
and histone acetylation the most widely studied modifications. Epigenetic therapeutic 
agents have targeted the reversible nature of these modifications with some clinical 
success. The aim of this study was to characterise the molecular consequences of 
treatment of MDS and AML cells with the histone deacetylase inhibitor (HDACi) 
Romidepsin. 
Romidepsin as a single agent induced cell death with an increasing dose and 
time profile associated with increased acetylation of histone H3 lysine 9 (H3K9) and 
decreased HDAC activity. Gene expression profiling, qPCR, network and pathway 
analysis recognised that oxidation-reduction was involved in response to Romidepsin. 
ROS was implicated as being involved post-treatment with the involvement of TSPO 
and MPO. 
Genomic analysis uncoupled the differences in protein-DNA interactions and 
gene regulation. The spatial and temporal transcriptional differences associated with 
acetylated, mono- and tri-methylated H3K9, representative of two activation and 
a repression mark respectively, were identified. Bioinformatic analysis uncovered 
positional enrichment and transcriptional differences between these marks; a degree 
of overlap with increased/decreased gene expression that correlates to increased/
decreased histone modification. Overall, this study has unveiled a number of 
underlying mechanisms of the HDACi Romidepsin that could identify potential drug 
combinations for use in the clinic.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a 
heterogeneous group of clonal haematopoietic disorders 
characterised by bone marrow failure and disease-
associated anaemia, thrombocytopenia and neutropenia. 
Concomitant leukemic transformation for approximately 
one third of MDS patients, which is more difficult to treat, 
will occur resulting in truncated survival [1, 2]. 
The majority of patients are elderly, >60 years, 
with reduced performance status, other co-morbidities 
and ineligible for transplantation. High-risk patients, 
who are ineligible for transplantation, can be treated with 
intensive chemotherapy (IC) or treatment with low-dose 
cytarabine (LDAC) [3]. However, neither has the ability 
to consistently prolong survival in high-risk MDS with 
a similar outcome to treatment with best supportive care 
[4–6]. This highlights the need for better tolerated and 
more molecularly targeted therapies for these patients. 
Epigenetic therapies such as DNA methyl transferase 
inhibitors (DNMTi) and histone deacetylase inhibitors 
(HDACi) have been used in clinical trials as single 
agents or in combination with other epigenetic drugs, 
chemotherapy or other novel molecular therapies [7–9]. 
HDACs regulate cell cycle progression, survival 
and angiogenesis and therefore are a potential therapeutic 
target in a variety of malignancies [10]. HDACi are used 
to shift the equilibrium of histone and non-histone protein 
acetylation resulting in a modification of the epigenetic 
landscape and changes in the expression, functionality 
and localisation of non-histone proteins [11, 12] including 
the tumour suppressor p53 [13]. Six distinct groups of 
HDACi have been developed each with different structural 
integrities and selectivity profiles as pan inhibitors (e.g. 
Vorinostat) or with more specific inhibitory effects on 
selected HDACs (e.g. Entinostat). One such specific 
HDACi used for the inhibition of Class I HDACs is 
Romidepsin, a bicyclic tetra-peptide that has been FDA 
approved for the treatment of cutaneous T-cell lymphoma 
and undergoing clinical trials for the treatment of other 
malignancies [14–16]. Furthermore, Romidepsin has been 
identified as a potential therapeutic for MLL-rearranged 
infant acute lymphoblastic leukemia [17]. 
The mechanism of action of Romidepsin remains 
to be fully elucidated and this study has investigated 
the underlying mechanism of action of Romidepsin at 
the cellular and molecular level to identify potential 
therapeutic targets for further combination therapies.
RESULTS
Romidepsin results in a reduction in cell viability, 
altered protein acetylation and changes in cell 
cycle
A dose response was performed to identify the 
pattern of response on cell viability following treatment 
with Romidepsin. The IC50 (inhibiting 50% of 
proliferative capabilities) was deduced following analysis 
of an increasing range of doses from 0.1–5 nM Romidepsin 
(Figure 1A and 1B). The sensitivity to the drug was in the 
nM range for all three cell lines, with 72 hour IC50 values 
between 1–1.8 nM. Dose responses were conducted on 
two AML patient samples (LREC: 08/NIR1/9) which also 
showed a dose and time dependent decrease in viability of 
these cells post-Romidepsin treatment (Figure 1C). 
As it has been documented that Romidepsin 
preferentially results in acetylation of lysine residues on 
histone 3 (H3) over that of histone 4 (H4) [18], the levels 
of acetylation on H3 lysine 9 (H3K9) were measured 
following treatment with increasing doses of Romidepsin. 
Figure 2A shows the increase in acetylation of H3K9 
following treatment with 0.5 to 5 nM at 24 hours, with 
increased acetylation also observed with the lower doses 
by 72 hours. Romidepsin preferentially inhibits HDACs 1 
and 2; if HDAC 6 was inhibited the levels of acetylation 
on non-histone proteins such as α-Tubulin should also 
increase. However, as shown in Figure 2B, no increase in 
acetylation of α-Tubulin was seen, therefore Romidepsin 
does not inhibit the activity of HDAC 6 in this instance. 
Due to the increases in acetylation of histone 
proteins observed at 24 hrs (Figure 2A), a candidate 
dose of 1.5 nM was mainly used for subsequent studies. 
This dose resulted in an increase in acetylation but not 
in an overt amount of cell death that could be attributed 
to cytotoxicity. As demonstrated in Figure 2C, this dose 
had the potential to induce marked acetylation by 24 hours 
whilst sparing levels of HDAC 1 protein. However, this 
also implies that a reduction in levels of HDAC 1 is not 
necessary to result in increased acetylation but potentially 
blocks activity of that HDAC. To explore this further, the 
levels of HDACs specific to Class I and II in OCI-AML3 
cells were investigated across a range of Romidepsin doses 
(Figure 2D). A gradual reduction in HDAC activity with 
0.5 and 1.5 nM Romidepsin at time points up to 24 hrs 
was seen; whilst higher doses display a greater reduction 
in activity as early as 12 hrs. This correlated with the 
increased in acetylation of H3K9 in Figure 2C. 
HDAC inhibitors have been linked with altering the 
cell cycle and whilst there was an increase in the Sub G0 
population with an associated reduction in all other phases 
of the cell cycle with increasing doses, lower doses had 
little to no effect on cell cycle. No evidence of apoptotic 
behaviour was observed at 0.5 nM, with modest levels 
detected at 1.5 nM with cells entering early phase apoptosis 
by 48 hr and late phase by 72 hrs (Supplementary Figure 1). 
The higher dose of 5 nM results in detection of early phase 
apoptosis by 24 hr and 80% apoptosis by 72 hr. 
Gene expression profiling following Romidepsin 
treatment 
Affymetrix HG U133 plus 2.0 arrays were used to 
perform gene expression profiling on SKM1 cells treated 
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with DMSO or 1.5 nM Romidepsin. The candidate dose of 
1.5 nM Romidepsin was selected based on the data collected 
in the previous sections, including a minimal effect on cell 
viability but with the ability to induce molecular effects such 
as an increase in acetylation concomitant with a decrease in 
HDAC activity. Stringent criteria were applied following 
an ANOVA of all genes which included the application of 
an unadjusted p-value = <0.05 and a fold change of ≤ and 
≥ 1.5. These criteria were applied to identify significantly 
differentially expressed genes and those which are deemed 
to have changed to a biologically relevant degree. This 
generated a gene list consisting of 487 probe-sets that were 
significantly differentially expressed between control and 
treated sets; the 487 probe-sets represented 442 genes. Of 
these 487 differentially expressed probe-sets, 484 (99%) 
were significantly up-regulated versus only 3 (1%) down-
regulated (Figure 3A). Pathway analysis (Figure 3B) using 
the online tool DAVID identified oxidation reduction 
as the most significantly enriched pathway, followed by 
bio-synthetic processing and regulation of apoptosis. A 
total of 38 (7.8%) genes from the gene list were validated 
by RQ-PCR (Figure 3C) and these were associated with 
oxidation and reduction including MARC1 and 2, WWOX 
and ADI1 with a large number of cytochrome family 
members also included. Genes involved in nitrogen and 
carboxylic acid biosynthetic processing included PAPSS1, 
ATP6V0E2, AGPAT1 and CD74, whilst those involved in 
regulation of apoptosis consisted of ADAMTSL4, ATG5 
and TRAF5. Gene ontology (GO) enrichment scores for 
biological processes and molecular functions are shown 
in Supplementary Figure 2. Further network connectivity 
was performed using the online database STRING to 
identify known and predicted protein-protein interactions. 
Supplementary Figure 3 shows networks identified 
in STRING which were then imported into Gephi for 
visualisation. TSPO was at the centre of a highly connected 
node with a high degree of betweenness centrality, 
implying this protein may be essential for the response to 
Romidepsin (Figure 3D). The activation of TSPO either by 
ligand or cholesterol can result in the release of ROS from 
the outer mitochondrial membrane with, as yet, unknown 
consequences on downstream effectors [19]. Interestingly, 
other nodes were centred on an increased expression of 
FYN and CBL, both of which are associated with ROS 
activation. 
Histone H3 profiling using ChIP-Seq following 
treatment with Romidepsin 
The known Romidepsin target Histone H3 was 
selected analysis by chromatin immunoprecipitation 
sequencing (ChIP-seq) profiling focusing on lysine 
Figure 1: Dose dependent response of Romidepsin in cell lines and patient samples. (A) OCI-AML3, SKM-1 and MDS-L 
cell lines treated with a dose range of Romidepsin with cell viability being assessed using the Cell Titer Glo® Assay at 24, 48 and 72 hours. 
IC50 values were determined based on cell line and time using GraphPad Prism software. (B) IC50 (nM) and range for Romidepsin for the 
three cell lines at each time point (24 hr, 48 hr and 72 hr). (C) Romidepsin treated patient samples over 24, 48 and 72 hours showing dose 
and time dependent reduction in cell viability following treatment as measured using Cell Titer Glo®.
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9 modifications; H3K9ac, H3K9me and H3K9me3. 
This allowed for the analysis of two activation marks 
(H3K9ac and H3K9me) alongside one repression mark 
(H3K9me3) following 24 hour treatment with 1.5 nM 
Romidepsin on SKM-1 cells. The acetylation of TSPO, 
which we had shown to be differentially expressed, was 
used as a marker of successful enrichment of H3K9ac 
(Supplementary Figure 4). The software SICER 1.1 
was used to generate a list of genomic co-ordinates that 
showed increased and decreased enrichment for each mark 
following Romidepsin treatment: 21,940 peaks showed 
increased H3K9ac with only 2,453 decreased; H3K9me 
was increased at 16,734 peaks and decreased at 1,094; 
and increased H3K9me3 was seen at 30,024 peaks with 
only 352 peaks showing a decrease. Further positional 
enrichment was done using the criteria for: H3K9ac of ± 
1000 bp from the transcriptional start site and not in the 
gene body; H3K9me within the gene body; and H3K9me3 
of within –2000 to +200 bp of the TSS and within the 
gene body (Supplementary Figure 5). The overlap of 
gene regions using the positional enrichment criteria for 
three marks reduced the number of relevant increased and 
decreased gene regions across all three histone marks and 
suggested that there was some degree of overlap within 
the increased islands cohort (Figure 4A), but very little 
overlap with the decreased islands (Figure 4B). 
Further, we overlapped the increased and decreased 
islands for each mark, using the positional enrichment 
criteria with the 4,488 differentially expressed genes 
identified from the microarray analysis. Reassuringly, there 
were no genes that were common to both increased and 
decreased islands for any of the mark that overlapped with 
microarray data. Interestingly, the group with the largest 
proportion of overlap with the microarray data (Figure 4C–
4E) is with that of increased acetylation whereby 130 genes 
overlap (Supplementary Table 1; Supplementary Figure 6). 
DISCUSSION
A plethora of epigenetic modifying drugs are 
currently being examined both in the pre-clinical and 
clinical setting. DNA demethylating drugs, such as 
Azacitidine, have proven successful in the treatment of 
high-risk MDS and AML after receiving FDA approval 
in 2004. Although harbouring the potential to extend 
survival by 9.5 months, little is known about the precise 
Figure 2: Romidepsin effects histone and protein acetylation. (A) Western blot analysis of OCI-AML3, SKM-1 and MDS-L 
cells for H3K9ac following increasing concentrations of Romidepsin at 24 and 72 hours showing that all the cell lines were susceptible 
to a dose dependent increase in levels in acetylation by 24 hours and with lower doses by 72 hour following treatment. (B) Protein 
expression analysis by western blot measuring levels of acetylated alpha tubulin in OCI-AML3 and SKM-1 at 24 hours. Romidepsin is a 
selective HDAC inhibitor for HDACs 1 and 2, and 4 and 6 to a lesser extent. Acetylated α-Tubulin is a substrate of HDAC 6. Treatment 
with Romidepsin had a limited effect on HDAC 6 does not result in an increase in acetylation of α-Tubulin. (C) Protein expression using 
western blot analysing levels of HDAC 1 and H3K9ac following treatment with 1.5 nM Romidepsin showing no change in HDAC1 
protein expression after treatment over a 24 hour time period, but that by 24 hour there is an increase in acetylation of H3K9 with 1.5 nM 
Romidepsin. (D) OCI-AML3 cells were treated with varying doses of Romidepsin over a 24 hour time frame. Class I and II HDAC activity 
levels were measured using the HDAC-Glo™ I/II assay and demonstrated a reduction in HDAC activity commensurate with an increase in 
acetylation. Results are representative of a biological and technical triplicate and as a percentage of DMSO control. 
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mechanism of action that is involved eliciting response 
following treatment. Another of the new generation 
epigenetic modifying drugs which has also been used 
in a clinical setting is the histone deacetylase inhibitor 
(HDACi) Romidepsin. It received FDA approval in 
2009 for the treatment of cutaneous and peripheral T 
cell lymphoma [15], however little is known about its 
underlying mechanism of action. As single agents, HDACi 
do not produce the expected survival responses in patients 
and so with that, it is hypothesised that combinations of 
these epigenetic drugs may induce synergistic effects 
[11, 12] and increase survival probability in patients. 
This study aimed to extrapolate the underlying 
mechanism of action of the HDAC inhibitor Romidepsin 
with the potential of identifying differentially expressed 
genes, novel pathways and downstream effects that 
could be explored as targets for rational combinations for 
potential use in the clinic.
Romidepsin has been used in patients with 
cutaneous T-cell lymphoma (CTCL) and peripheral T-cell 
lymphoma (PTCL), however, very little has been explored 
in the context of MDS/AML [20] and response to the drug 
has been termed sub-optimal for use as a single agent 
[21]. Furthermore, a high-throughput screening revealed 
Romidepsin enhanced the activity of a key component 
of infant ALL therapy, cytarabine (ARAC) in vitro and 
in vivo [17]. It has been used in the treatment of MDS/
AML as a Phase I clinical trial (ROMAZA, UKCRN 
Study ID: 15082) in combination with Azacitidine. 
Therefore, as limited pre-clinical data was available using 
Romidepsin in this setting, we have assessed the cellular 
and molecular effect in MDS/AML cell line models. A 
dose and time-dependent decrease in cell viability was 
observed with a subsequent increase in the proportion of 
apoptotic cells with a related increase in the proportion of 
cells in sub G0. There was a correlation with an increase 
in protein expression of acetylated histone H3K9 with 
increasing concentrations of Romidepsin and a preceding 
decrease in HDAC activity at earlier time-points. It has 
been previously been recognized that HDACIs induce 
Figure 3: Unsupervised hierarchical clustering heat-map of 487 differentially expressed probe-sets between DMSO 
and Romidepsin treated samples in SKM-1 cells. (A) Heat-map displaying a visual representation of differentially expressed genes 
between control group in green, along Y axis, and Romidepsin treatment in yellow on Y axis. Unsupervised hierarchical clustering was 
performed which generated these clusters based on treatment groups and on genes which are up and down-regulated. A clear separation 
between control and treatment group is visible with the vast majority (99%) of genes being up-regulated (red) following Romidepsin 
treatment. (B) Most significantly up-regulated processes as identified by DAVID following Romidepsin treatment on SKM-1. (C) 
Correlation of microarray log(2) intensity values and Ct values from real-time PCR of the 39 candidate genes. (D) Increased protein 
expression of TSPO following treatment with 1.5 nM Romidepsin over 72 hours in OCI-AML3 and SKM1 cells.
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acetylation of histone H3 at lower concentrations lower 
than those that induce cell death [18]. The increase in 
acetylation was independent of any observable differences 
in HDAC1 protein or gene expression. Acetylation of 
the cytoplasmic protein α-Tubulin remained unaffected 
following treatment; however this was an expected 
observation as Romidepsin is a selective HDAC inhibitor 
that does not target HDAC6, the binding partner of 
α-Tubulin. Romidepsin treatment contributes to these 
associated changes in cell cycle and has the potential to 
alter the expression of p21 [22] and the cell surface marker 
CD11b on OCI-AML3 and SKM-1 cells (data not shown).
Transcriptional analysis of 1.5 nM Romidepsin 
after 24 hrs identified 487 differentially expressed probe 
sets of which 484 were up-regulated compared to only 
3 down-regulated. These 487 probe-sets represent 442 
genes. Pathway and network analysis identified oxido-
reductase activity as the most significantly enriched 
pathway with hubs forming around genes associated 
with this pathway. The induction of oxidative injury 
has been seen with other HDACis [23]. One such gene 
in our pathway that was strikingly poignant was TSPO 
[24]. This was biologically significantly up-regulated 
following treatment with Romidepsin and also appeared 
to be central in the response to treatment. Network 
analysis also highlighted it as having a high degree of 
connection as well as forming a bottleneck–often deemed 
more biologically relevant than massive up-regulation 
of a single gene. TSPO is located in multiple sites, 
including haematopoietic and lymphatic cells and has 
Figure 4: Overlap in genes regions associated with increased and decreased islands across all three histone marks and 
differentially expressed genes. Gene regions associated with increased and decreased islands generated in SICER were imported to Partek 
for overlap analysis. Overlap of positional enriched regions showing increased (A) or decreased (B) acetylation/methylation for the three marks. 
Overlap of differential histone marks and differentially expression genes by microarray for H3K9ac (C), H3K9me (D) and H3K9me3 (E). 
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multiple functions [24]. It has since been shown to be a 
cholesterol-binding protein with the ability to transport 
cholesterol from intracellular stores to the mitochondria. 
It has also been linked with ROS production and one 
theory is that external stimulus will alter TSPO activity 
and ultimately result in the opening of mitochondrial 
membrane pores [25]. This may lead to the production of 
ROS which can impact on several pathways downstream, 
but that an immediate release of cytochrome C through 
membrane pores such as BAX will initiate mitochondria-
mediated apoptosis. Although further investigation 
will be required, ROS was implicated in other ways in 
this study and in the literature as being associated with 
HDACi treatment [26, 27]. 
Our next aim was to explore the effect that 
Romidepsin had on histone H3 activation/repression status 
whilst integrating this with the differentially expressed 
genes. Three histone marks, acetylated, monomethylated 
and trimethylated H3K9, were chosen as representative of 
two activation marks and a repressive mark respectively. 
The integration of the transcriptional program for this 
setting provided a more comprehensive view of what is 
being differentially regulated on H3K9 [28]. Uniquely 
enriched peaks were identified in the normalised 
Romidepsin samples using SICER and these peaks were 
then analysed to ascertain their positional enrichment prior 
to peak annotation. From here, gene lists were produced 
that were specific to each individual mark based on their 
positional enrichment. Overlap was identified between 
all three marks in both increased and decreased islands, 
signifying that there is the potential for genes to harbour 
enrichment of all three marks which could be as a result of 
cells not all being synchronised to the same phase of the 
cell cycle. This could also represent a somewhat dominant 
effect of certain marks on their ability to exert an active or 
repressive effect, but that will require further investigation 
to fully elucidate this potential. There was also a degree 
of overlap observed with increased and decreased 
enrichment on individual marks, again something that 
could be as a result of cells not being synchronised. 
Integration with microarray data suggested that there were 
130 genes associated with increased gene expression and 
enrichment of H3K9 acetylation, implying activation of 
these genes. Only 32 genes were associated with increased 
trimethylation on H3K9 and gene expression, indicating 
a role in repression of these genes following treatment 
with Romidepsin. Whilst it is recognised that further 
analysis and investigation of the genes and networks is 
required, this study has suggested that there are potential 
Romidepsin induced targets, such as ROS, for rationale 
combination therapies for AML/MDS patients. 
MATERIALS AND METHODS
Materials
Romidepsin (Celgene Inc., USA) was dissolved in 
DMSO at a stock concentration of 100 mM; however the 
final DMSO concentration for in vitro assays was always 
at 0.1%.
Cell lines
OCI-AML3, MDS-L and SKM-1 cells (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen 
GmbH, Braunschweig, Germany), were maintained in 
RPMI-1640 media supplemented with 10% fetal calf 
serum, 1% Pen/Strep and incubated in 5% CO2 at 37° C. 
Viability, caspase activity assays 
Cell viability and caspase activity was determined 
using the CellTitre-Glo luminescent viability kit and 
caspase Glo assays (Promega, Madison, USA) as 
described in the manufacturer’s instructions. 
FACS analysis
To assess cell cycle changes, cells were harvested 
and re-suspended in 70% ice-cold ethanol overnight 
followed by staining with propidium iodide mix (40 µg/mL 
PI, 2 ng/ml RNase A). BD FITC Annexin V apoptosis 
detection kit (BD Biosciences, California, USA) was used 
according to the manufacturer’s instructions to assess 
apoptosis. Samples were analysed using LSRII and BD 
FACSDiva software.
Western blot analysis
Cells were washed and lysed using RIPA buffer 
(50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA, 
1% triton X (x100) and 0.1% SDS containing protease 
inhibitor cocktail tablets (Roche Products Ltd, Welwyn 
Garden City, UK) and phosphatase inhibitors (sodium 
fluoride and sodium orthovanadate). Protein concentration 
was quantified (Pierce BCA Protein Assay kit, Thermo 
Fisher Scientific, USA). Total lysates were prepped 
by adding 10X loading buffer to 30 µg of total lysate, 
denatured for 5 minutes at 95° C. Lysates were then 
electrophoresed on various percentage Tris Glycine gels 
and immunoblotted using anti-actin (Sigma, UK), anti-
acetylated tubulin (Cell signalling, Massachusetts, USA), 
anti-hyperacetylated histone H3 (Merck Millipore, UK), 
anti-HDAC1 and anti-TSPO (Abcam, UK) antibodies.
Quantitative real-time PCR 
RNA was extracted using the RNeasy® kit (Qiagen, 
Crawley, U.K.) and was eluted using RNase-free water 
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and experiment was performed in accordance with 
manufacture’s protocol. The High Capacity Reverse 
Transcription Kit (Applied Biosystems, Life Technologies, 
UK) was used for the conversion of RNA to cDNA in 
accordance with manufacturer’s instructions. 
Sybr-Green real time quantitative PCR was 
performed using the 7900HT Real-time PCR system 
under optimal cycling condition. Primers used for mRNA 
quantification were designed in-house using Primer-
Blast and purchased from Eurofins Genomic (Eurofins 
Genomic, Ebersberg, Germany). Primer sequences used 
can be found in Supplementary Table 2. Validation of 
microarray studies was carried out using RNA matched 
samples to those used for hybridisation to the Affymetrix 
arrays.
Gene expression is shown as fold change of the 
control treatment and normalised to the endogenous 
controls. The Ct value for each gene was normalised to 
β-Actin and 18S endogenous controls (ΔCt), ΔCt was then 
normalised to the treatment control (ΔΔCt), and the ΔΔCt 
was used to calculate gene expression changes as a fold 
change over control.
Analysis of gene expression by microarray 
RNA was extracted from biological triplicate 
samples using the RNeasy kit. A maximum of 8 µg of total 
RNA was processed to cRNA and hybridised to Affymetrix 
Human Genome U133 Plus 2.0 Arrays using an Affymetrix 
GeneChip Hybridisation Oven and following the protocol 
outlined by Roche Diagnostics (Burgess Hill, UK). Arrays 
were then stained using an Affymetrix GeneChip Fluidics 
Station 450 and scanned using the Affymetrix GeneChip 
Scanner 3000 5G. Analysis of data was performed using 
Partek Genomic Suite Software (Partek Incorporated, 
Missouri, USA). Following CEL file importation to Partek 
Genomic Suite, data were analysed using a Robust Multi-
array (RMA) analysis to correct for background, quantile 
normalise and summarise the probe set intensity into 
expression measurements. 
ChIP-qPCR
A total of 1 × 106 cells per IP were harvested from 
drug treated cells and fixed in 1% formaldehyde. Cells 
were washed and chromatin was isolated; fixed samples 
were suspended in LB1 buffer (50 mM Hepes-KOH, pH 
7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% 
IGEPAL, 0.25% Triton X-100) for 10 minutes, pelleted 
and suspended in LB2 buffer (10 mM Tris-HCl, pH8, 
200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) for 
5 minutes, pelleted and suspended in LB3 buffer (10 mM 
Tris-HCl, pH8, 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.1% NA-deoxycholate, 0.5% N-laurylsarcosine). 
Cells were sonicated for 9 minutes to obtain fragments 
of between 200–500 bp. Following sonication, 10% 
triton X-100 was added and chromatin was snap frozen 
for chromatin immunoprecipitation studies. To pre-
block beads and conjugate to antibody; 30 µL beads per 
IP were washed and blocked overnight at 4° C in sterile 
0.5% BSA:PBS. Chromatin was immunoprecipitated 
with chosen antibodies (anti-histone H3 (acetyl K9), 
Anti-histone H3 (mono methyl K9) and Anti-histone H3 
(tri methyl K9) (Abcam, UK) and eluted using 20 µL 
of elution buffer (50 mM Tris pH8, 10 mM EDTA, 1% 
SDS). Chromatin was purified using the QIAquick PCR 
purification kit (Qiagen) as described in the manufacturer’s 
instructions.
ChIP-Seq 
Chromatin Immunoprecipitation followed by DNA 
sequencing (ChIP-Seq) was performed. The process 
is described by Schmidt et al. in 2009 [29] and in brief 
involves cross-linking proteins to DNA followed by 
fragmentation of these complexes to 200–500 bp. Upon 
confirmation of appropriately sized fragments, sheared 
chromatin is then bound to an antibody of choice to be 
immuno-precipitated before cross-links are reversed with 
proteinase K and DNA is purified. The eluted DNA then 
underwent adapter ligation and library preparation with 
a size selection stage prior to being sequenced using an 
Illumina® Next-Seq 500.
Statistical analysis
All statistical analysis was performed using 
Graphpad Prism version 5 for Windows (California, 
USA). All statistical tests were performed on at least a 
biological replicate of 3.
Analysis software and packages
Partek® Genomic Suite™ Software was used for 
analysis of all microarray data for visualisation and 
exploratory analysis. STRING v 10 - Search Tool for 
the Retrieval of Interacting Genes was used for network 
analysis of gene lists produced (127) and Gephi v 0.8.2-beta 
used for network visualisation and manipulation. DAVID v 
6.7 - Database for Annotation, Visualization and Integrated 
Discovery was the web-accessible program used for all 
pathway analysis (128,129). R version 3.2.0 was used 
(https://www.r-project.org) in the background of several of 
the packages used in ChIP-Seq analysis. ChIP-Seq packages 
included; Trim Galore! v 0.4.0, FASTQC v 0.11.3, Bowtie2 
v 2.2.5, SAMTools v 1.2, BEDTools v 2.17.0, SICER v 1.1, 
PASPT v 1.0, CEAS v 0.9.9.7 and IGV v 2.2.57. All ChIP-
Seq packages were run on Linux. 82. 
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